|
Match
|
Document |
Document Title |
|
|
5516632 |
Synthetic peptides
The present invention relates to immunogenic preparations of peptides comprising amino acid sequences corresponding to antigenic determinants of the envelope glycoprotein of HTLV-I or HTLV-II...
|
|
|
5510328 |
Compositions that inhibit wound contraction and methods of using same
The present invention provides methods for reducing or inhibiting wound contraction in a subject having a wound comprising administering to the subject a pharmaceutical composition comprising a...
|
|
|
5510333 |
Inhibitors of Cathepsin G and elastase for preventing connective tissue degradation
Novel compounds which are chemically linked inhibitors of the proteases Elastase and Cathepsin G prevent connective tissue degradation associated with neutrophil induced inflammatory disease.
|
|
|
5506208 |
Method for using synthetic analogs of thrombospondin for inhibiting angiogenesis activity
Methods of use of compounds and compositions comprising fragments and synthetic analogs of human thrombospondin are provided for promoting or inhibiting thrombospondin-like activity.
|
|
|
5504069 |
Inhibition of trauma-induced tumor growth
A method for inhibiting in a mammal the accelerated growth of a solid primary or metastatic tumor resulting from tissue trauma caused surgically, non-surgically, or by tissue ulceration, which...
|
|
|
5502036 |
Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain
Disclosed herein are pentapeptide derivatives of the formula X--NR 1 --CH(R 2 )--C(W)--NH--CR 3 (R 4 )--C(W 2 )--NR 5 --CH CH 2 C(O)--Y!--C(W 3 )--NH--CR 6 -- CR 7 (R 8 )--COOH!--C(W 4...
|
|
|
5502032 |
Peptides, the preparation and use thereof
Novel peptides of the formula ##STR1## in which R 1 , R 2 , X, A, R 3 , B, D, E, R 7 , M, Q, a, b and d have the meanings stated in the description, and the preparation thereof are described. The...
|
|
|
5498601 |
Platelet aggregation-inhibiting peptides
Novel peptide derivatives having RGD as a basic structure were found which have a platelet aggregation-inhibiting action, blood coagulation-inhibiting action and cell adhesion-inhibiting action....
|
|
|
5494894 |
Agent for the regulation of the appetite or a sleeping agent
An agent for the regulation of the appetite or a sleeping agent, which consists of the activation peptide in procolipase, consisting of the peptide sequence X-Pro-Y-Pro-Arg wherein a) X is Ala...
|
|
|
5492894 |
Compositions for treating wrinkles comprising a peptide
The present invention relates to topical compositions comprising a peptide having the formula Q a -(Xaa) n -Q c wherein Q a is selected from the group consisting of hydrogen, alkyl, aryl,...
|
|
|
5487898 |
Compositions and method for the sublingual or buccal administration therapeutic agents
Pharmaceutical compositions for the sublingual or buccal administration of therapeutic agents which are normally degraded upon oral administration comprise such a therapeutic agent, a solvent,...
|
|
|
5484771 |
Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus
Described herein are peptide derivatives of the formula R 1 NH--CO--Q--C(O)--NR 2 --CH[CH 2 C(O)--Y]--C(O)--NH--CH[CR 3 (R 4 )--COOH]--C(W)--NH--CHR 5 --Z wherein R 1 is an optionally...
|
|
|
5484770 |
Peptide compounds which inhibit the proliferation of epidermal or epithelial stem cells
Pentapeptides and derivatives thereof, including derivatives having one or more additional amino acids inserted in the sequence and/or added at the C- and N-termini, have been found to possess good...
|
|
|
5482923 |
Heparin neutralization with platelet factor 4 fragments
Circulating heparin in a mammal may be neutralized without substantial depletion of platelets or leukocytes by administering to the mammal a heparin neutralizing amount of a purified heparin...
|
|
|
5478809 |
TAN-1511, its derivatives, production and use thereof
A compound of the formula: ##STR1## wherein each R 1 , R 2 and R 3 is an aliphatic acyl group, X is an amino acid sequence consisting of 1 to 5 amino acid residues which contain at least one...
|
|
|
5478808 |
2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
A compound of the formula: ##STR1## wherein each of R 1 and R 2 is hydrogen or aliphatic acyl, A is amino which may be protected, X is an amino acid sequence consisting of 1 to 10 amino acid...
|
|
|
5476841 |
Inhibitors of herpes viral ribonucleotide reductase
Peptide derivatives are of the formula A--B--D--NHCH{CH 2 C(O)R 1 }C(O)--NHCH{CR 2 (R 3 )--COOH}C(O)--E wherein A is a lower alkanoyl bearing two substituents, each substituent selected...
|
|
|
5476840 |
New hexapeptidic derivatives, preparation process and use as medicaments of these new derivatives
New peptidic derivatives having the general formula (I): X 1 X 2 X 3 Ile X 5 X 6 wherein X 1 is hydrogen, a rest of histidin, of acetyl-histidin or of D-histidin, X 2 is a rest of alanin, of...
|
|
|
5470831 |
Angiogenic peptides
The present invention relates to peptides and peptide derivatives related to platelet factor 4 which exhibit angiogenic activity, to pharmaceutical compositions comprising said peptides, and to...
|
|
|
5468730 |
Methods for the treatment of non-IgE-mediated diseases
Methods and compositions for the treatment of non-Ige-mediated inflammatory response or disease conditions are described.
|
|
|
5464820 |
Specific inhibitors of tissue kallikrein
The invention is directed to substrate analogs which are specific for tissue kallikrein. These analogs contain a sequence which corresponds to at least positions 388 to 390 of human kininogen, and...
|
|
|
5464819 |
Physiologically active peptide having immunoregulatory activities
A novel, substantially pure, physiologically active peptide is disclosed, comprising an amino acid sequence selected from Gly-Glu (SEQ ID NO. 5), Pro-Val-Val (SEQ ID NO. 6), Glu-Pro-Val-Val (SEQ ID...
|
|
|
5462954 |
Substituted phenyl phenol leukotriene antagonists
Antagonists having a substituted phenyl phenol or a substituted phenolic biphenyl structure, and various derivatives thereof, are specific leukotriene antagonists. Their structures, use and...
|
|
|
5462927 |
Peptides aiding nerve regeneration
Biologically active peptides are disclosed of the formula: A 1 --A 2 --A 3 --A 4 --Phe--Arg--TrP--A 5 , or a pharmaceutically acceptable salt thereof; A 1 is H or acetyl; A 2 is Ala, or...
|
|
|
5461035 |
Short peptides with insulin activity
A method for the treatment of diabetes mellitus or non-insulin-dependent diabetes comprising at least one peptide selected from the group consisting of Tyr-Gln-Leu-Glu-Asn-Tar-Cys-Asn,...
|
|
|
5459129 |
Condensed heterocyclic compounds, their production and use
A novel compound of the formula: ##STR1## wherein a ring A stands for an optionally substituted 5-membered ring; B stands for an optionally substituted divalent cyclic or chain group; either one of...
|
|
|
5455227 |
Biologically active lipoprotein and its use
A lipoprotein possessing pulmonary surfactant activity comprising an alveolar polypeptide or protein and, covalently bound thereto, one or two fatty acid residue(s); a pharmaceutical composition...
|
|
|
5455228 |
Peptidase resistant thrombin receptor peptide ligand
A peptide ligand analogue of peptide ligands derived from thrombin-cleaved thrombin receptor site on platelets resists inactivation by aminopeptidase M by substituting the β-amino acid isoserine...
|
|
|
5449661 |
Angiotensin converting enzyme inhibitor and method for preparing same
An angiotensin converting enzyme inhibitor contains as an effective constituent Val-Pro-Pro and contains 3 to 10 amino acid residues. A method for producing the aforementioned angiotensin...
|
|
|
5444042 |
Method of treatment of neurodegeneration with calpain inhibitors
The present invention provides a method of treating a neurodegenerative pathology in a human patient. This method includes selecting a patient for monitoring for the presence of a neurodegenerative...
|
|
|
5436221 |
Tumor metastasis inhibiting compounds and methods
A peptide derivative containing 1 to 20 units of peptide unit represented by the following general formula [I] or a pharmaceutically acceptable salt thereof; [Z]--Arg--X--Asp--[Y] ...
|
|
|
5430021 |
Hydrophobic drug delivery systems
A pharmaceutical preparation including a drug incorporated into hydrophobic particles comprised of long chain carboxylic acid or ester thereof or long chain alcohol, wherein the particles are...
|
|
|
5428020 |
Cysteine (NPYS)-containing peptides and use thereof for inhibiting platelet aggregation
Peptides and pharmaceutically acceptable salts thereof of the following formula are provided ##STR1## wherein R is selected from the group consisting of Leu, Ile and Val, X is from zero to four...
|
|
|
5428016 |
Antimicrobial peptide and antimicrobial agent
An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as...
|
|
|
5428116 |
Synthesis of complex polyamines for ampholyte production
New synthesis and analysis procedures for novel crosslinked polyamines and ampholytes. Polyamines are crosslinked with tartaric acid ester, malonic acid ester, or polycarboxylic acid esters of the...
|
|
|
5411942 |
Peptide derivative, pharmaceutical preparation containing it and method for treatment of glaucoma
Peptide derivatives of 3-5 optionally substituted amino acids, a process for preparing the peptides, a pharmaceutical composition containing at least one peptide derivative active against glaucoma...
|
|
|
5411943 |
Hepatoma treatment with somatostatin analogs
A method for treating liver cancer in a mammalian subject. The method includes administering to the subject a composition which contains a therapeutically effective amount of an octapeptide of the...
|
|
|
5411956 |
Lipolytic enzyme inhibitors
A lipolytic enzyme inhibitor is disclosed which comprises as an active ingredient at least one of a basic protein, a basic polypeptide and salt thereof. The inhibitor is useful as a dieting agent...
|
|
|
5409894 |
Method of preventing balloon catheterization blood vessel damage
Somatostatin analogues and derivatives in free form or in pharmaceutically acceptable salt or complex form are useful for preventing or reducing neointimal proleferation following angioplasty.
|
|
|
5409900 |
Porphycene compounds for photodynamic therapy
A porphycene having the structure ##STR1## wherein each R 1 is, independently, (a) --(CH 2 ) n --X, where n=1-4, X is OR 2 and R 2 is C 1 -6 alkyl, aralkyl or aryl; CN; OH; OSO 2 R 2 ; NH 2 ...
|
|
|
5407916 |
Neurotensin mimetics as central nervous system agents
Neurotensin mimetics are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as...
|
|
|
5403843 |
Pyrrolopyrimidinyalglutaminate derivatives and their use
A condensed pyrimidine derivative of the formula (I): ##STR1## wherein the ring A stands for an optionally substituted 5-membered ring; B stands for an optionally substituted divalent 5- or...
|
|
|
5403824 |
Methods for the treatment of osteoporosis
Methods of treatment for osteoporosis in a human or other animal subject, comprising administering to said subject a safe and effective amount of an active selected from the group consisting of...
|
|
|
5401648 |
Peptides having peptidyl transferase inhibiting activity and methods of use thereof
5-mer and 8-mer polypeptides have been demonstrated to inhibit peptidyl transferase and according constitutes synthetic antibiotics. Identified, sequence-specific peptides effective include ...
|
|
|
5393740 |
Neurotensin Hexapeptides
A hexapeptide represented by formula (II): A-B-Pro-C-D-E (I) where A represents an L- or D- form of arginine or lysine whose N-terminal amino group is...
|
|
|
5382569 |
Endotherlin antagonists
Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute...
|
|
|
5380668 |
Compounds having the antigenicity of hCG
Disclosed are compounds having antigenic binding affinity with antibodies directed against human chorionic gonadotropin. The compounds typically include or consist of an oligopeptide with the...
|
|
|
5378691 |
Amino acid derivatives
New amino acid derivatives of the formula I R 1 --C p H 2p --(NH) y --CO--NH--CHR 2 --CO--Z--C m H 2m --CO--NH--CHR 3 --CR 4 --(CHR 5 ) n --CO--E--Q--Y I in...
|
|
|
5374621 |
Neurotensin method for inhibiting vascular leakage
A method of retarding vascular leakage caused by tissue injury comprises administering a neurotensin or a neurotensin analog (SEQ ID NO: 1) at dosages sufficient to prevent or retard injury induced...
|
|
|
5374623 |
Cysteine protease inhibitors effective for in vivo use
A method of treating medical conditions with proteinase inhibitors of the formula: ##STR1## wherein B is H or an amino acid blocking group for the N-terminal amino acid nitrogen; R 1 is an...
|